1	Fine-mapping a genome-wide meta-analysis of 98,374 migraine cases identifies 181
2	sets of candidate causal variants
3	
4	Heidi Hautakangas ^{1*} , FinnGen**, International Headache Genetics Consortium**,
5	HUNT All-in Headache**, Aarno Palotie ^{1,2,3} , Matti Pirinen ^{1,4,5*}
6	
7	1. Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science
8	(HiLIFE), University of Helsinki, Helsinki, Finland. 2. Analytic and Translational Genetics
9	Unit, Department of Medicine, Department of Neurology and Department of Psychiatry
10	Massachusetts General Hospital, Boston, MA, USA. 3. The Stanley Center for
11	Psychiatric Research and Program in Medical and Population Genetics, The Broad
12	Institute of MIT and Harvard, Cambridge, MA, USA. 4. Department of Public Health,
13	University of Helsinki, Helsinki, Finland. 5. Department of Mathematics and Statistics,
14	University of Helsinki, Helsinki, Finland.
15	
16	* Correspondence to: heidi.hautakangas@helsinki.fi and matti.pirinen@helsinki.fi
17	** A list of authors and their affiliations appears at the end of the paper.
18	
19	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21

22 Migraine is a highly prevalent neurovascular disorder for which genome-wide 23 association studies (GWAS) have identified over one hundred risk loci, yet the 24 causal variants and genes remain mostly unknown. Here, we meta-analyzed three migraine GWAS including 98,374 cases and 869,160 controls and identified 122 25 26 independent risk loci of which 35 were new. Fine-mapping of a meta-analysis is 27 challenging because some variants may be missing from some participating studies 28 and accurate linkage disequilibrium (LD) information of the variants is often not 29 available. Here, using the exact in-sample LD, we first investigated which statistics 30 could reliably capture the quality of fine-mapping when only reference LD was 31 available. We observed that the posterior expected number of causal variants best 32 distinguished between the high- and low-quality results. Next, we performed fine-33 mapping for 102 autosomal risk regions using FINEMAP. We produced high-quality 34 fine-mapping for 93 regions and defined 181 distinct credible sets. Among the high-35 quality credible sets were 7 variants with very high posterior inclusion probability (PIP > 0.9) and 2 missense variants with PIP > 0.5 (rs6330 in NGF and rs1133400 in 36 INPP5A). For 35 association signals, we managed to narrow down the set of 37 38 potential risk variants to at most 5 variants.

- 39
- 40

41 Introduction

42

43 Migraine is a common neurological disorder characterized by recurrent disabling
44 episodes of severe headache that are typically one-sided, pulsating in nature, and

45 accompanied by other symptoms such as nausea, and hypersensitivity to light 46 and/or sound. It has two main subtypes, migraine without aura and migraine with aura. The aura is a reversible visual, sensory or speech disturbance, that typically 47 48 occurs before the headache phase. Migraine attacks last usually from 4 to 72 hours, 49 and can significantly harm daily life of patients¹. Migraine was ranked as the second 50 most disabling disease worldwide in terms of years lived with disability by Global 51 Burden of Diseases Study in 2019². Its lifetime prevalence has been estimated to be 52 about 15 to 20 % worldwide, and it is three times more common in females than in 53 males². Family and twin studies estimate the heritability to be about 40%³. To date, over 100 migraine associated loci have been reported by GWAS^{4,5,6,7,8,9,10,11,12,13,14}. 54 55 The genetic association of migraine has shown a general enrichment in genes highly 56 expressed in vascular and central nervous system related tissues^{15,13} but we lack 57 detailed information on specific genetic variants that affect the migraine risk.

58

59 Identification of causal genes and variants that have a biological effect on migraine is crucial for understanding the biology of migraine, and for developing new effective 60 61 treatments for the disorder. Here, we aim to narrow down correlated genetic variation in migraine associated regions to a smaller number of candidate causal variants by 62 applying statistical fine-mapping¹⁶. Fine-mapping methods evaluate how plausibly 63 64 each variant in the region is among the causal variants by utilizing the observed association statistics and the LD structure of the region¹⁶. Multiple methods that can 65 utilize GWAS summary statistics have been developed, including PAINTOR¹⁷, 66 CAVIAR¹⁸, FINEMAP¹⁹, JAM²⁰ and SuSIE²¹. The optimal way to apply fine-mapping 67 is to compute the LD information from the original GWAS data (in-sample LD), but 68 69 when the original genotype data are unavailable, approximate LD information is often

obtained from a reference genotype panel (reference LD). However, when reference
LD is used, the discrepancy from the in-sample LD can cause errors in fine-mapping
and this problem becomes more severe as the GWAS sample size grows²².

73

74 Even though large meta-analyses have become a successful way to increase 75 statistical power of GWAS, they remain difficult to fine-map reliably for several 76 reasons²³. First, meta-analyses are combinations of multiple studies and typically no 77 single analyst has access to the exact in-sample LD of the whole meta-analysis, 78 which means that reference LD must be used. Second, differences in genotyping 79 platforms and genotype imputation pipelines between the meta-analyzed studies can 80 bias the fine-mapping results. Third, some variants included in the meta-analysis 81 may be present in only a subset of the studies, which leads to variation in information 82 content of the association statistics of different variants. In a landmark fine-mapping study on schizophrenia, Trubetskoy et al. (2022)²⁴ avoided these problems by 83 84 collecting all genotype-phenotype data into a single analysis site. Unfortunately, to 85 our knowledge, no other international disease consortium has been able to create a 86 comparable analysis environment that would allow an in-sample fine-mapping of a large meta-analysis. Given that fine-mapping of meta-analysis results typically relies 87 88 on reference LD, a crucial question is how we can assess when the results of fine-89 mapping based on reference LD are reliable.

90

So far, the largest GWAS meta-analysis on migraine contained 102,084 cases and
771,257 controls from 25 study collections¹³. Unfortunately, we cannot perform
reliable fine-mapping for that meta-analysis, since the in-sample LD is not available.
Instead, we conducted a migraine meta-analysis with 98,374 migraine cases and

95 869,160 controls by combining data from three sources: 23andMe, Inc., FinnGen, 96 and UK Biobank (UKB). Of these data sets, 23andMe and UKB were included in the 97 earlier meta-analysis of Hautakangas et al. (2022) while FinnGen was not. Statistical 98 power of our meta-analysis was comparable to the previous migraine meta-analysis 99 of Hautakangas et al. (2022), with effective sample sizes of 339,000 and 326,000, 100 respectively. Importantly, we have the full in-sample LD available for 26 risk loci and 101 for the remaining risk loci we have the in-sample LD for FinnGen and UKB but not for 102 23andMe (Table 1). This set-up allowed us to investigate how different LD reference 103 panels perform compared to the in-sample LD. In particular, we evaluated different 104 statistics that could be used to assess fine-mapping guality when only reference LD 105 is available. Finally, we utilized our results to fine-map 102 migraine risk loci to 106 narrow down the putative causal variants behind the associations. We were able to 107 get reliable fine-mapping results for 93 out of 102 regions and identified 7 variants 108 with a high probability (>90%) of being causal and two missense variants, rs6330 in 109 *NGF* and rs1133400 in *INPP5A*, with a probability > 50% of being causal.

- 110
- 111 Table 1. Three study collections included in the migraine meta-analysis.

Study	Ancestry	Cases	Controls	N	Case %	Migraine definition	LD availability
UK Biobank	European, British	10,881	330,169	341,050	0.03	Self-reported	In-sample
23andMe, Inc	European descent	53,109	230,876	283,985	0.19	Self-reported	In-sample for 26/102 fine- map regions
FinnGen R8	European, Finnish	34,385	308,114	342,499	0.10	Medication purchases	In-sample
Meta- analysis	European descent	98,374	869,160	967,534	0.10	Self-reported, medication purchases	In-sample 26/102, reference LD 76/102

112

114 Results

115

116	We conducted an inverse-variance weighted meta-analysis on migraine by
117	combining results from the three GWAS (Table 1): UK Biobank (UKB; 10,881 cases
118	and 330,169 controls), 23andMe, Inc. (53,109 cases and 230,876 controls), and
119	FinnGen Release 8 (34,385 cases and 308,114 controls). The total sample size is
120	98,374 migraine cases and 869,160 controls. Before meta-analyzing the data, we
121	estimated pairwise genetic correlations between the study collections by LD Score
122	regression (LDSC) ²⁵ . The estimated genetic correlations were 1.00 (s.e. 0.04)
123	between UKB and 23andMe, 0.84 (s.e. 0.05) between UKB and FinnGen, and 0.87
124	(s.e. 0.03) between 23andMe and FinnGen. The lower genetic correlation between
125	FinnGen and the other two studies could be due to differences in the case definitions
126	(triptan purchases in FinnGen vs. self-reporting in UKB and 23andMe). A
127	comparable level of genetic correlation (0.81) has been reported before between
128	primary care and self-reported migraine cases within UKB ²⁶ . Another source of
129	possible heterogeneity in effect sizes is the difference in genetic ancestry (Finnish in
130	FinnGen vs. Non-Finnish European in the other two).
131	

132 The genomic inflation factor (λ_{GC}) of the migraine meta-analysis was 1.38. There was 133 a linear relationship between the association statistic and the LD-score

(Supplementary Fig 1) indicating that the polygenic background of migraine was the main source of the genomic inflation. However, as the intercept from LDSC was elevated to 1.09 (s.e. 0.01) from its null value of 1.0, some inflation could also be due to confounding factors such as cryptic relatedness, population stratification or other model misspecification. Consequently, we further checked the LDSC intercepts for

the individual studies: 1.03 (s.e. 0.01) for 23andMe, 1.00 (s.e. 0.01) for UKB and
1.10 (s.e. 0.01) for FinnGen. The higher intercept for FinnGen could be due to a
different GWAS analysis method (whole genome-regression by REGENIE²⁷
including related samples) compared to UKB and 23andMe (logistic regression
excluding related samples). Estimated SNP-heritability was 11.49% (s.e. 0.47%)
from LDSC when population prevalence was assumed to be 16%.

145

We followed the locus definition of Hautakangas et al. (2022) and defined the LD-146 147 independent genome-wide significant (GWS; $P < 5 \times 10^{-8}$) risk loci from the metaanalysis iteratively by choosing the variant with the smallest P-value as an index 148 149 variant and excluding all other GWS variants with LD $r^2 > 0.1$ to that index variant 150 from further considerations until no GWS variants remained. Next, we formed a high LD region around each index variant extending to the level of $r^2 > 0.6$, and merged 151 152 regions that were closer than 250 kb. Lastly, all other GWS variants were included in 153 their closest region, and the region boundaries were updated, and once again regions closer than 250 kb were merged (see further details in Methods). Based on 154 155 this locus definition, we identified 122 LD-independent risk loci, of which 35 were 156 new (Table 2), and 87 overlapped with the previously known risk loci (Fig 1, Supplementary Table 1, Supplementary Figs 2-4)^{4,5,6,7,8,9,10,11,12,13,14}. 157 158 We observed statistically significant heterogeneity (P < 0.05/122) in effect sizes 159 between the study collections only for two lead variants, both of which resided in the 160 previously known migraine loci (PRDM16 and near ZCCHC14)(Supplementary Table 161 1, Supplementary Fig 3). As external replication data of 34,807 cases and 193,475 controls, we meta-analyzed data from the Trøndelag Health Study (HUNT)²⁸ and 162 163 IHGC16 migraine meta-analysis excluding the Finnish cohorts and the 23andMe

164data⁹. Of the 35 lead variants of our new loci, 32 were consistent in direction (P = 2.1165 $\times 10^{-7}$, one-sided binomial test) and 17 replicated with P < 0.05 (one-sided test;</td>166Supplementary Table 2) in the replication data. When we meta-analyzed the167discovery and the replication data, 28 out of the 35 novel loci remained GWS168(Supplementary Table 2).169

170 To define the fine-map regions, we merged together the risk loci that were closer

171 than 1.5 Mb. This resulted in 102 fine-map regions. To avoid problems due to

172 varying sample sizes across the variants, we included in fine-mapping only

autosomal SNPs that were available in all three cohorts. This criterion reduced the

174 number of common variants (MAF>0.05) per regions on average by 19%.

175

Figure 1. A Manhattan plot of the inverse-variance weighted fixed effects migraine meta-analysis including 98,374 cases and 869,160 controls. X-axis presents the chromosomal location and y-axis the $-\log_{10}(P$ -value). Known loci are highlighted in purple and new loci in green. Variants with posterior inclusion probability (PIP) > 0.9 and missense variants with PIP > 0.5 in high-quality fine-mapping regions are annotated.



184 Table 2. New 35 migraine risk loci identified from the meta-analysis of 98,374

185 migraine cases and 869,160 controls.

Locus name	RSID	Chrom osome	Position GRCh37	Effect allele	Other allele	Effect allele frequency	Log- odds ratio	S.e.	P-value
near RUNX3	rs71014329	1	25348950	1	D	0.604	0.034	0.005	2 57E-10
ST3GAL3	rs783302	1	44366341	G	Δ	0.878	0.007	0.008	1.68E-09
SE3B4	rs7544531	1	149897217	т	C	0.070	0.072	0.000	5.08E-09
	re61830764	1	212280076	Δ	G	0.004	0.072	0.012	3.71E-08
	re112706054	2	68810060	G	Δ	0.002	0.001	0.000	7.88E-16
	rs2305142	2	98375722	G	Δ	0.023	0.137	0.005	1 18E-08
near GPD2	rs74482068	2	157560108	D	1	0.022	0.076	0.000	1.76E-08
near RANP7	rs11386839	3	22929430	D		0.500	0.029	0.005	7.68E-09
	rs10026792	4	2862190	G	A	0.687	0.032	0.005	2.79E-09
EPHA5	rs147908403	4	66362482	c	т	0.054	0.069	0.012	2.80F-09
ITGA1	rs4865540	5	52184268	с С	A	0.820	0.037	0.007	1.41F-08
near GI RA1	rs372257780	5	151200938	-	D	0.599	0.033	0.006	2.27F-09
KCNIP1	rs78151838	5	170108683	A	G	0.905	0.054	0.010	1.82E-08
MAMI 1	rs10794701	5	179181061	A	G	0.119	0.043	0.008	3.57E-08
near COX19	rs117303395	7	1001963	A	G	0.019	0.122	0.022	4.40F-08
MAD1I 1	rs10479762		2045351	т	с С	0.419	0.029	0.005	8.01F-09
FLAVI 2	rs10966033		23705736	G	т	0.617	0.029	0.005	2.70E-08
near ZCCHC7	rs10973207	9	37100525	т	G	0.187	0.042	0.007	1.04E-10
near I MX1B	rs4358894	9	129464802	C	G	0.513	0.030	0.005	3.33E-09
near DENND5A	rs34494849	11	9287030	С	т	0.768	0.034	0.006	1.17E-08
near MTCH2	rs11039324	11	47665686	G	A	0.601	0.030	0.005	9.76E-09
MRE11A	rs639311	11	94205747	С	т	0.681	0.033	0.005	9.02E-10
IPO8	rs12369125	12	30807195	A	с	0.251	0.036	0.006	7.08E-10
MGAT4C	rs73187675	12	86409247	т	A	0.193	0.037	0.006	6.08E-09
RP11-562L8.1	rs1957110	14	29777492	т	с	0.409	0.029	0.005	1.59E-08
INSM2	rs2296919	14	36005659	т	с	0.807	0.038	0.006	3.44E-09
RPS6KA5	rs117151272	14	91415550	A	т	0.026	0.097	0.018	3.59E-08
near ONECUT1	rs1899730	15	53166138	т	G	0.707	0.032	0.006	2.11E-08
FAM174B	rs12910861	15	93218540	с	т	0.227	0.037	0.006	2.15E-09
FAM65A	rs9934328	16	67573367	с	G	0.137	0.049	0.007	1.32E-11
TUBG2	rs2292750	17	40811781	с	т	0.452	0.030	0.005	3.53E-09
near NRTN	rs76899991	19	5822370	G	т	0.963	0.077	0.014	2.89E-08
SYMPK	rs74821481	19	46320041	G	т	0.678	0.036	0.005	4.59E-11
near SERHL2	rs141478056	22	42939927	G	А	0.120	0.046	0.008	2.23E-08
near FTHI 17	rs149675702	23	31063624	с	т	0.945	0.079	0.014	4.56E-08

186 RSID = reference SNP ID, GRCh37 = Genome Reference Consortium Human Build
187 37, s.e. = standard error. Alleles D and I refer to deletion and insertion, respectively.
188

189 Comparison of different LD panels in fine-mapping

190

191 A common problem in meta-analyses is that the in-sample LD is not available, and 192 use of reference LD may lead to biased results. Figure 2 demonstrates this problem 193 at the locus around TSPAN2 where fine-mapping using the in-sample LD disagrees 194 strongly with the UKB reference LD but agrees well with a more accurate UKB-FG 195 reference LD. This shows that, in our setting, fine-mapping based on the UKB-FG 196 reference LD has a potential to yield reliable results but that we need some way to 197 assess, for each region, whether the reference LD has provided reliable results. 198 Therefore, we evaluated whether some statistics, either derived from the GWAS 199 results or from the fine-mapping results, could flag the regions where the reference 200 LD produced unreliable fine-mapping results compared to the in-sample LD. We did 201 this comparison in the 26 regions where the in-sample LD was available. As 202 candidate statistics, we considered: (1) posterior expectation of the number of causal 203 variants (PENC), and, from the top variant(s) of the credible sets, (2) maximum 204 pairwise r², (3) maximum marginal *P*-value, and (4) minimum INFO value. We used 205 the maximum difference of the variant-specific posterior inclusion probabilities 206 $(\max \Delta)$ between the reference LD and the in-sample LD to assess the quality of the 207 referce LD results. A small max Δ value (close to 0) indicates high quality (the 208 reference LD produces similar results to the in-sample LD), and a large value (close 209 to 1) indicates low quality (the reference LD produces different results from the in-210 sample LD).

In general, both LD reference panels performed well in most of the 26 regions
available for this comparison, but, as expected²², the more accurate UKB-FG panel
performed clearly better than the UKB panel alone. For example, max∆ was above
0.1 only in 2/26 regions with the UKB-FG panel but in 8/26 regions with the UKB
panel (Fig 3a).

216

Figure 2. Fine-mapping a region near *TSPAN2* at chromosome 1 using three

different LD sources. a) Plot of the GWAS results with the chromosomal location on

219 x-axis and the strength of the association as -log10 *P*-values from the inverse-

variance weighted fixed-effect meta-analysis with 98,374 migraine cases and

221 869,160 controls on y-axis. Variants are colored based on the squared correlation

222 (r²) to the two variants in the top configuration suggested by FINEMAP with the in-

sample LD. The suggested top configurations based on three LD panels are marked

by lines with the in-sample LD and the UKB-FG reference LD giving the same top

225 configuration and the UKB reference LD including three additional variants

226 (highlighted in green). Posterior inclusion probabilities (PIPs) for the variants based

227 on b) in-sample LD, c) UKB-FG reference LD and d) UKB reference LD.



229

230 We then investigated how well the four different statistics could separate the regions 231 with low-quality fine-mapping results from those with high-quality results for the two 232 LD reference panels (Supplementary Fig 5). First, when PENC was used, both LD 233 reference panels performed similarly for the regions where FINEMAP suggested only 234 one or two causal variants (Supplementary Fig 5a). Those results were also close to 235 the in-sample results (max Δ < 0.07). All low-quality regions (with max Δ > 0.1) had PENC > 2 with the UKB panel and PENC > 3 with the UKB-FG panel. Thus, we used 236 these PENC thresholds to define low-quality regions when the in-sample LD was not 237 available. We expect that these thresholds have a high sensitivity for low-quality 238

239 results but will simultaneously exclude some of the regions that truly have many 240 causal variants. The other three statistics are not able to distinguish the low-quality regions as clearly as PENC (Supplementary Figs 5b-d). First, the maximum r² 241 242 among the top configuration variants does not distinguish both of the low-guality 243 regions with the UKB-FG panel (Supplementary Fig 5b). Additionally, neither the 244 maximum *P* nor the minimum INFO within the top credible set variants separates 245 well the low-quality regions from the good-quality regions (Supplementary Figs 5c,d). We conclude that PENC gives the best separation among the statistics investigated. 246 247 Previously, PENC has been used to filter FINEMAP results in the schizophrenia finemapping study²⁴. 248 249 250 Next, we evaluated how PENC classifies the 76 fine-map regions where only 251 reference LD was available to us. The 76 grey points in Figure 3b show that the fine-252 map regions without the in-sample LD are typically having PENC < 2.5 and, with the 253 UKB-FG LD, only 6 of the 76 regions have PENC > 3. 254 Figure 3. a) Scatter plot comparing the maximum PIP differences (max^Δ) between 255 256 the in-sample and reference LD for 26 fine-map regions. X-axis shows the UKB-FG reference LD and y-axis the UKB reference LD. b) Strip chart shows the posterior 257 258 expected number of causal variants (PENC) from fine-mapping for the two LD 259 reference panels for the 102 fine-map regions. Red dots indicate large differences 260 from the in-sample LD (max Δ > 0.1), and grey color indicates regions for which only 261 reference LD is available and therefore max Δ is not known. Horizontal line shows 262 PENC = 3 that we use as a threshold to define reliable results with the UKB-FG 263 panel.









267

268 Figure 4. Summary of the fine-mapping results across the 102 migraine risk regions.



269

Overall, for a majority of the fine-map regions, FINEMAP suggested one (42%) or 270 271 two (46%) causal variants (Supplementary Table 3, Fig 4.). The 102 fine-map 272 regions together had 181 distinct signals when the signals were defined by the number of causal variants per region with the highest posterior probability. Among 273 274 the 76 regions without the in-sample LD, 6 had PENC above 3. We flagged these

275 regions to be of low-quality, and their interpretation requires extra caution. The 276 largest PENC observed was 5 and it occurred for two fine-map regions: PRDM16 (index variant rs10218452) and HOXB3 (index variant rs2555111). Of these, HOXB3 277 278 region is flagged as low-quality because there is no in-sample LD available. 279 The sizes of 95%-credible sets ranged from 1 to 2,787 variants, and 49 credible sets had 10 variants or less. A very high PIP (≥ 0.9) was observed for 10 variants 280 281 (Supplementary Table 4), of which seven were in the high-quality fine-map regions 282 (Table 3). We conducted a look-up from Variant Effect Predictor (VEP) database for 283 all credible sets to search for variants that could have an impact on the gene 284 transcript. In total, 149 unique missense variants were found of which 3 had PIP > 285 0.5: rs6330 (PIP=0.59) in NGF located at chromosome 1, rs1133400 (PIP=0.93) in 286 INPP5A located at chromosome 10 and rs28929474 (PIP=0.64) in SERPINA1 located in a low-quality fine-map region at chromosome 14 (Table 3, Supplementary 287 288 Table 5). Of these, rs6330 is a significant *cis*-eQTL for *NGF-AS1* expressed in atrial 289 appendage of heart and rs28929474 for IFI27L2 expressed in tibial artery and in left 290 ventricle of heart in GTEx v.08 data. 291 *NGF* encodes protein nerve growth factor beta (NGH β) that is important in the development and survival of neurons, and involved in transmission of pain, 292 293 temperature, and touch sensations via sensory neurons. It binds to two receptors, NTRK1 encoded by *NTRK1* and NGFR/p75^{NTR} encoded by *NGFR*. Of note, two 294 295 additional missense variants among the credible sets, rs6339 (PIP= 0.48) and 296 rs6336 (PIP=0.39), are located in NTRK1 in a separate locus. The missense variant 297 rs6330 shows association with multiple diseases of the musculoskeletal system and 298 connective tissue including spinal stenosis, spondylosis, spondylopathies and hallux

valgus in FinnGen R10 PheWAS scan, all to the opposite direction compared to themigraine risk (Supplementary Table 6).

INPP5A encodes a membrane-associated type I inositol 1,4,5-trisphosphate 5-301 phosphate protein, which hydrolyzes Ins(1,4,5)P3 leading to the mobilization of 302 303 intracellular calcium. It has a central role in various cellular signaling processes 304 including neurotransmission, hormone secretion, cell proliferation and muscle 305 contraction. INPP5A is highly expressed in Purkinje cells of cerebellum, and in mice studies its deletion have been shown to cause ataxia and cerebellar 306 degeneration^{29,30}. 307 308 SERPINA1 encodes an alpha-1 antitrypsin, a serine protease inhibitor protein, that 309 belongs to the serpin superfamily. Its primary target is elastase, and other targets are 310 plasmin and thrombin. Several mutations, including our high-PIP variant 311 rs28929474C>T, in SERPINA1 can cause an autosomal co-dominant genetic 312 disorder alpha-1 antitrypsin (AAT) deficiency, which can lead to lung or liver disease due to reduced alpha-1 antitrypsin levels³¹. A missense variant rs28929474 is highly 313 314 pleiotropic and shows associations to multiple disease categories in PheWAS of 315 FinnGen R10 data including, for example, diseases of the respiratory system, diseases of the circulatory system, diseases of digestive system, pregnancy related 316

diseases, diseases of the nervous system, and diseases of musculoskeletal systemand connective tissue (Supplementary Tables 6-8).

Five additional high-impact variants on protein function (1 stop gained, 2 start lost, and 2 splice acceptor variants) were among the credible sets, but only with modest PIPs below 0.01 (Supplementary Table 5), and another 5 variants with high-impact on something else than protein coding function (long non-coding RNA, antisense or nonsense mediated decay) with PIPs below 0.02.

324	Our results provided new information on two of the strongest known migraine risk
325	loci by estimating PIPs of 1.00 for the intronic variants rs9349379 in PHACTR1 and
326	rs11172113 in <i>LRP1</i> . We were able to fine-map both of these loci by using the in-
327	sample LD. The candidate variant in PHACTR1 is also associated with many
328	vascular diseases and its effects on gene expression of the genes in the locus have
329	been studied in detail but with contradicting results ^{32,33} . Also, the candidate variant in
330	LRP1 is associated with several vascular diseases, such as sporadic thoracic aortic
331	dissection, fibromuscular dysplacia and spontaneous coronary artery
332	dissection ^{34,35,36} . The LDL receptor-related protein 1 (LRP1) is a cell surface receptor
333	and has an important role in vascular and blood brain barrier integrity ^{37,38,39} . It is
334	expressed in almost every tissue, and most studied in liver and brain. LRP1 is also
335	involved in vascular calcium signaling by regulating smooth muscle cell
336	contractility ³⁸ . A recent study suggested that <i>LRP1</i> expression is regulated by allele-
337	specific mechanism of intronic rs11172113 located in an enhancer region through
338	two transcription factors (MECP2 and SNAIL) ⁴⁰ .

Table 3. Variants with high (>0.9) posterior inclusion probability (PIP) and missense

Gene (VEP)	Predicted consequence (VEP)	RSID	Chro moso me	Position GRCh37	Effect allele	Othe r allele	PIP	Minor allele freque ncy	Log- odds ratio	S.E.	P-value	LDsource
PHACTR1	Intron variant	rs9349379	6	12903957	G	A	1.000	0.422	-0.084	0.005	2.59E-60	in-sample
LRP1	Intron variant	rs11172113	12	57527283	С	Т	1.000	0.404	-0.101	0.005	7.27E-85	in-sample
-	Intergenic variant	rs12445022	16	87575332	A	G	1.000	0.333	-0.035	0.005	1.04E-10	in-sample
-	Intergenic variant	rs12136718	1	156409585	A	G	0.999	0.072	0.046	0.010	1.95E-06	in-sample
ELAVL2	Intron variant	rs10966033	9	23705736	Т	G	0.954	0.383	-0.029	0.005	2.70E-08	UKB-FG
TLX3	3' UTR variant	rs918472	5	170738836	G	А	0.932	0.292	-0.029	0.006	1.95E-07	UKB-FG
INPP5A	missense variant	rs1133400	10	134459388	G	A	0.926	0.198	0.039	0.006	5.06E-10	UKB-FG
NGF	missense variant	rs6330	1	115829313	A	G	0.593	0.461	0.033	0.005	4.97E-11	in-sample

342 variants with PIP > 0.5 among the 93 high-confidence fine-map regions.

343

344	Due to the restriction of including in fine-mapping only the variants that are available
345	in all three data sets, the original lead variant was missing in 17/102 fine-map
346	regions (Supplementary Table 3b). In 14/17 of these regions, the original lead variant
347	was represented by one of the top credible set variants (defined as being in LD with
348	r2 > 0.1 in the UKB data). For the remaining 3 regions, the signal related to the
349	original lead variant may be missing from the fine-mapping results, and we flagged
350	these regions to be of low-quality. Among the fine-map regions for which the lead
351	variant was included in the analysis, the lead variant was within the 95% credible
352	sets in 83/85 fine-map regions and within the top configuration in 73/85 of the
353	regions.
354	
355	Phenome-wide association scans for the credible set variants
356	

We conducted three separate phenome-wide association studies (PheWAS) by
using data from FinnGen Data Freeze 10 including 429,209 individuals. First, by a

359	PheWAS for the 181 credible set top variants and the list of 2,399 FinnGen
360	endpoints excluding the migraine endpoints, we identified 404 variant-disease
361	associations with $P < 1 \times 10^{-5}$ (Supplementary Table 6, phewas_app). Of these, 108
362	variant-disease associations belonged to diseases of the circulatory system,
363	including, for example, hypertension and ischemic heart disease, followed by 39
364	variant-trait associations in a category of quantitative endpoints, including, e.g.,
365	height and BMI, 34 in diseases of the musculoskeletal system and connective tissue
366	category, including, e.g., spinal stenosis and rheumatoid arthritis, and 28
367	associations in diseases of the respiratory system, including, e.g., asthma and
368	COPD.
369	Second, for the 159 functional variants among the credible sets, we conducted a
370	targeted PheWAS scan within neurological and cardiovascular endpoints, and
371	identified 122 variant-disease associations with $P < 1 \times 10^{-4}$ (Supplementary Table
372	7, phewas_app), including traits such as sleep apnea and stroke. Third, for the 307
373	variants with PIP > 0.1, with a similar targeted PheWAS scan within the neurological
374	and cardiovascular endpoints, we identified 330 variant-disease associations with P
375	< 1 × 10^{-4} (Supplementary Table 8, phewas_app), including, e.g., focal epilepsy and
376	hydrocephalus.
377	

378

379 Discussion

380

Well over one hundred risk loci for migraine have been reported from GWAS, but the causal variants and genes are still mostly unknown^{4,5,6,7,8,9,10,11,12,13,14}. Statistical finemapping of the GWAS results at the risk loci is a natural next step but reliable fine-

384 mapping of large meta-analysis data has turned out to be very difficult. Our recent migraine meta-analysis of 25 studies¹³ illustrated these difficulties as the accurate LD 385 information was not available and the sample size varied considerably across 386 387 variants. In this study, our goal was to provide reliable fine-mapping for migraine by 388 creating a new migraine meta-analysis for which accurate LD information was 389 available and sample size across variants was more stable. Despite the more 390 stringent selection criteria, the effective sample size of our new meta-analysis 391 (339,000) turned out to be comparable to that of the earlier meta-analysis (326,000). 392

393 A key guestion in fine-mapping a GWAS meta-analysis is how to assess the 394 reliability of the results. We were able to study this question by directly comparing 395 results between accurate in-sample LD and approximate reference panel LD. We 396 observed that the posterior expected number of causal variants (PENC) as reported 397 by FINEMAP distinguished well the regions with high-guality fine-mapping results 398 from those with low-guality results. We also observed that an appropriate PENC 399 threshold depends on the quality of the reference panel. In our case, we were able to 400 use an upper limit of 3.0 for PENC. While this upper limit restricts our ability to fine-401 map the migraine risk regions that truly have more than 3 causal signals, we expect 402 that the proportion of such regions is small, as only 3/26 (12%) of the migraine loci 403 with the in-sample LD had PENC over 3 in our analysis.

404

Here, we performed the first systematic fine-mapping of a migraine meta-analysis
and provided high-quality fine-mapping results for 91% of the migraine risk regions
identified by the meta-analysis. Our high-quality results highlight two missense

408 variants with high PIPs: rs6330 (PIP=0.59) in *NGF* and rs1133400 (PIP=0.93) in
409 *INPP5A*.

The variant rs6330 is only in weak LD ($r^2 = 0.04$) with the lead variant (rs12134493) 410 411 of its locus and was identified as a secondary signal in our fine-mapping. A recent study¹⁴ has also reported that the migraine association of rs6330 remained 412 413 statistically significant in a conditional analysis after adjusting for the stronger signal 414 (rs2078371) within the same risk locus. NGF has been reported to be highly expressed in hippocampus and cortex^{41,42} although according to the GTEx v8 data, 415 416 *NGF* does not show statistically significant expression in any brain tissue but shows 417 high expression in multiple other tissues, including, for example, ovary, tibial nerve, 418 arteries, visceral adipose, and heart. NGF levels have been reported to be elevated 419 in cerebrospinal fluid in chronic migraine patients compared to controls⁴³, and 420 decreased in blood serum of episodic migraine patients compared to controls and chronic migraine patients⁴⁴. In addition, we observed two additional missense 421 422 variants with considerable PIPs, rs6339 (PIP=0.48) and rs6336 (PIP=0.39), located 423 in *NTRK1* which encodes one of the two receptors for NGF. NGF and its receptors 424 have a central role in the pain perception, and elevated NGF levels have been observed also in many other chronic pain conditions, such as osteoarthritis and low 425 back pain^{45,46,47}. Multiple antibodies of NGF or small molecular inhibitors of the NGF 426 427 receptors have been developed and tested in clinical studies to treat chronic pain conditions, including low back pain and osteoarthritis^{48,49,50,51,52}. Even though some 428 429 candidate drugs have shown potential benefit relating to pain relief, an increased risk 430 of progressive osteoarthritis has been observed in a small group of the treated patients⁵², and therefore none of the drugs have yet received FDA approval. 431 432 Currently, other type of drug classes (p75 neurotrophin receptor fusion protein, LEVI-

04 (ClinicalTrials.gov ID: NCT05618782) and anti-NGF PEGylated Fab' antibody⁵³), 433 434 are being developed and in pre-clinical or clinical testing. In adults, after pain stimuli, NGF activates overexpression of other neuronal molecules, including calcitonin 435 gene-related peptide (CGRP) and substance P⁵². CGRP is involved in migraine pain, 436 437 and several effective monoclonal antibodies targeting either CGRP or its receptors have been developed to treat migraine^{54,55,56}. 438 Gene *INPP5A* is highly expressed in Purkinje cells of cerebellum⁵⁷ and involved in 439 multiple cellular signaling processes including neurotransmission, hormone 440 441 secretion, cell proliferation and muscle contraction through its role in the pathway 442 regulating intracellular calcium levels. The missense variant rs1133400 is in modest 443 LD (r2 = 0.36) with the lead variant of the locus (rs200314499) that was filtered out 444 from fine-mapping due to QC. For this locus, FINEMAP suggested two causal 445 variants (PENC = 1.65). PheWAS showed no other significant associations with this

446 missense variant.

447

448 Another important finding is in the PHACTR1 locus, which is one of the strongest 449 known migraine risk loci. There our fine-mapping suggested one causal variant (PENC = 1.29), with the lead variant rs9349379 being a clear candidate for being 450 451 causal with PIP of 1.00. In our FinnGen PheWAS, we detected also strong 452 associations between the variant and, for example, major coronary disease events $(P = 8.22 \times 10^{-52})$, ischemic heart disease $(P = 1.18 \times 10^{-38})$ and angina pectoris $(P = 1.18 \times 10^{-38})$ 453 = 7.71 \times 10⁻²⁶), all to the opposite directions compared to migraine risk. Because of 454 455 these well-known associations with multiple vascular diseases, this locus has been previously studied in detail but with contradicting results. Gupta et al. (2017)³² 456 457 reported that rs9349379 regulates upstream gene EDN1, whereas Wang et al.

458 (2018)³³ reported that they failed to replicate this endothelial rs9349379-EDN1 eQTL, 459 but instead showed that rs9349379 regulates the closest gene PHACTR1, confirming previous vascular rs9349379-PHACTR1 eQTLs. Further, Rubin et al 460 (2022)⁵⁸ observed that a loss of *PHACTR1* gene does not seem to have any effect 461 462 on the endothelial or smooth muscle cells of the transgenic mice, and suggested that PHACTR1 has no contribution to pathological vascular phenotype in mice through 463 464 cells involved in vascular physiology. Our fine-mapping has provided strong evidence that the lead variant rs9349379 is causal for migraine, but given that the 465 466 variant is intronic, our fine-mapping results alone do not provide direct evidence 467 through which gene or mechanism this association affects the disease risk. 468 469 Our study has some limitations. First, since reliable fine-mapping requires that we 470 exclude variants that are not present in all three component studies of our meta-471 analysis, it is possible that we exclude also some of the true causal variants. This is 472 a potential problem especially when some of the top variants of the fine-map region have been filtered out from fine-mapping. To identify the regions that are likely to be 473 474 affected by this problem, we studied the LD patterns between the fine-mapped variants and those top variants from the fine-map regions that were not included in 475 476 the fine-mapping analysis. For most (14/17) regions where the top variants were 477 missing from fine-mapping, the signal of the top variant was at least partly 478 represented by another variant in LD with the top variant. Additionally, since very 479 rare variants were not included in our analysis, we miss the true causal variants that 480 are rare. Since our variant set is not comprehensive, we must keep in mind that also variants that have a very high probability of being causal in our analysis may still 481 482 have such variants in high LD that were not included in our analysis. A valid

calibration of the PIPs would require that all potential causal variants were included
in the analysis. In practice, for common variants, this would require comprehensively
imputed data sets with no missing variants in any of the meta-analyzed studies, and,
for rare variants, availability of high coverage sequencing data. Currently, we do not
yet have such resources available in typical GWAS meta-analyses of common
diseases such as migraine.

489 Another limitation of our study relates to the phenotype definitions of different substudies. First, both the UKB and 23andMe GWAS are based on self-reported 490 491 migraine status, and therefore some other conditions, such as tension headache, 492 may have been wrongly reported as migraine for some cases. Second, the FinnGen 493 GWAS is based on triptan purchase data, which may represent a specific subset of 494 migraine patients. Triptans are not suitable for all migraineurs and, especially, they 495 are contraindicated in patients with cardiovascular diseases. Overrepresentation of 496 migraineurs without any cardiovascular diseases could lead some FinnGen PheWAS 497 associations where migraine risk alleles seem to have protective effect on 498 cardiovascular phenotypes. Observational studies have reported that both migraine 499 and cardiovascular disease risk in women are positively associated⁵⁹.

500

To conclude, we performed a migraine GWAS meta-analysis with 98,375 migraine cases and 869,159 controls and identified 122 risk loci of which 35 were new. We followed up the meta-analysis by the first systematic fine-mapping analysis of migraine risk loci and identified 7 variants with a high probability of being causal. In addition to providing new information about genetic risk of migraine, we also proposed how one could, in general, evaluate whether the fine-mapping results of each risk loci seem reliable based only on the output from the fine-mapping software

- 508 FINEMAP. While a definitive fine-mapping analyses will require more comprehensive
- 509 data than are currently available for the GWAS meta-analyses of common diseases,
- 510 our study shows how reliable and novel fine-mapping results can be extracted
- 511 already from the currently available data sets by a suitable analysis approach.

512	Methods
-	

- 513
- 514 Data
- 515
- 516 We performed a new migraine meta-analysis by combining summary statistics from
- 517 three migraine GWAS: UK Biobank (N= 341,050, 10,881 cases and 330,169

controls), 23andMe (N=283,985, 53,109 cases and 230,876 controls), and FinnGen

519 R8 (N= 342,499, 34,385 cases and 308,114 controls). By meta-analyzing the three

520 studies, the total sample size was 967,534 including 98,375 migraine cases and

521 869,159 controls.

522

523 UK Biobank: The UK Biobank project is a population-based prospective cohort study 524 that consists of over 500,000 participants aged 40-69 at recruitment collected from 525 several regions across the United Kingdom. The participants completed 526 guestionnaires and attended interviews and clinal examinations by a trained staff member. A detailed description of UK Biobank is provided elsewhere⁶⁰, and detailed 527 528 genotyping, guality control and imputation procedures are described at the UK 529 Biobank website (https://www.ukbiobank.ac.uk/). We used the migraine GWAS data 530 described in¹³ with self-reported migraine as the phenotype. UK Biobank received 531 ethical approval from the North West Multi-centre Research Ethics Committee 532 (MREC) and informed consent has been obtained from all participants.

533

534 23andMe: 23andMe migraine GWAS was performed by a personal genomics

535 company 23andMe, Inc. (https://www.23andme.com/) and detailed description of the

536 migraine GWAS is provided elsewhere⁸. All participants have provided informed

consent and filled an online survey according to 23andMe's human subjects
protocol, which was reviewed and approved by Ethical & Independent Review
Services, a private institutional review board. Briefly, migraine cases were assessed
from the participants that had reported migraine or answered "Yes" to any of the
questions related to migraine, and controls from participants that did not report
having migraine or answered "No" to all of the questions related to migraine,
excluding participants with discordant answers.

544

545 FinnGen: FinnGen (https://www.finngen.fi/en) is a large biobank study that has 546 collected and genotyped 500.000 Finns and combined these data with longitudinal 547 registry data including The National Hospital Discharge Registry, Causes of Death 548 Registry and medication reimbursement registries, all of these linked by unique 549 national personal identification codes. FinnGen includes prospective and 550 retrospective epidemiological and disease-based cohorts and hospital biobank 551 samples. A detailed description of FinnGen is provided in⁶¹. We used the 8th Data Freeze for the migraine GWAS. The migraine cases were defined as the individuals 552 553 who had at least one triptan purchase and the remaining individuals without any triptan purchases were defined as controls from the social insurance institution of 554 555 Finland (KELA) registry including medication reimbursement and drug purchases 556 (https://r8.risteys.finngen.fi/phenocode/MIGRAINE TRIPTAN). 557 FinnGen participants provided informed consent under the Finnish Biobank Act. 558 Older cohorts with study-specific consents were transferred to the Finnish biobanks 559 after approval by Fimea, the National Supervisory Authority for Welfare and Health. 560 Recruitment protocols followed the biobank protocols approved by Fimea. The

- 561 Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa
- 562 (HUS) approved the FinnGen study protocol (Nr HUS/990/2017).
- 563 The FinnGen study is approved by Finnish Institute for Health and Welfare (permit
- 564 numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
- 565 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
- 566 THL/1524/5.05.00/2020), Digital and population data service agency (permit
- 567 numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social
- 568 Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018,
- 569 KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019,
- 570 KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers
- 571 THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020,
- 572 THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020,
- 573 THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021,
- 574 THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020,
- 575 THL/2658/14.06.00/2021, THL/4235/14.06.00/2021 and Statistics Finland (permit
- 576 numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)
- 577 TK/1735/07.03.00/2021).
- 578 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen
- 579 Data Freeze 8 include: THL Biobank BB2017_55, BB2017_111, BB2018_19,
- 580 BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26,
- 581 BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank
- 582 HUS/359/2017, Auria Biobank AB17-5154 and amendment #1 (August 17 2020),
- 583 AB20-5926 and amendment #1 (April 23 2020), Biobank Borealis of Northern
- 584 Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 §
- 585 /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 &

586 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB587 2018001.

588

We have access to the complete in-sample LD information for the UK Biobank and 589 590 FinnGen samples via the individual-level genotype data. Additionally, we have 591 access to the in-sample LD-matrices in 23andMe data for 26 of our fine-map regions. 592 Thus, for the 26 fine-map regions, we are able to do a high-quality fine-mapping 593 based on the in-sample LD while, for the remaining 76 regions, we need to apply an 594 LD reference panel that does not perfectly match the LD information corresponding 595 to our GWAS summary statistics. To assess the effect of the LD reference panel, we 596 formed two reference panels from the available LD information: one including data only from the UK Biobank (UKB), and the other combining the LD matrices from UK 597 598 Biobank and FinnGen (UKB-FG), as explained in section "Fine-mapping". 599 600 Genetic association analyses

601

The UK Biobank and 23andMe GWAS had been conducted by logistic regression on
 migraine (using PLINK2⁶² or custom software of the 23andMe Research Team,

respectively), and the FinnGen GWAS by a whole-genome regression model for a
binary trait with REGENIE²⁷.

All the samples were of European descent. Related individuals had been excluded by using a kinship value threshold of 0.0442 computed by KING⁶³ from UK Biobank, and by using a minimal expected amount of sharing between first cousins from a segmental identity-by descent algorithm from 23andMe. For the FinnGen GWAS

analysis, REGENIE accounted for the genetic relatedness by default, and thereforeno relatedness exclusions were applied.

612	We excluded multi-allelic variants, and variants with minor allele frequency (MAF) <
613	0.01, IMPUTE2 info or MACH r^2 < 0.6, and when available, missingness > 0.05 and
614	Hardy-Weinberg equilibrium (HWE) $P < 1 \times 10^{-6}$ from each study. Consequently, we
615	are only considering biallelic common variants in this work. We recoded indels as
616	insertions (I) and deletions (D). We mapped the FinnGen GWAS summary statistics
617	positions from hg38 to hg37 by UCSC LiftOver ⁶⁴ . We excluded the SNPs with an
618	effect allele frequency (EAF) discrepancy of >0.30 and indels with an EAF
619	discrepancy of >0.20 compared to UK Biobank from each study following
620	Hautakangas et al. 2022.
621	We conducted an inverse-variance weighted fixed-effects meta-analysis to combine
622	the three studies by GWAMA ⁶⁵ with 11,316,120 variants, of which 7,062,924 variants
623	were available in all three studies.
624	
625	Genetic correlation and SNP-heritability using LD Score regression
626	
627	We estimated genetic correlations between the three GWAS and SNP-heritability
628	from the migraine meta-analysis by LD Score regression v1.0.066,25 with
629	precomputed 1000 Genomes European LD Scores
630	(https://data.broadinstitute.org/alkesgroup/LDSCORE/) limiting the analysis to the
631	HapMap3 SNPs. We used munge-tool to reformat and perform additional quality
632	control for all GWAS summary statistics prior to the genetic correlation estimation.
633	We obtained a liability scale SNP-heritability estimate ⁶⁷ by using a population
634	prevalence of 16% for migraine.

635

636 Locus definition

637

638 We followed the locus definition of Hautakangas et al. (2022) and defined an LDindependent genome-wide significant (GWS, $P < 5 \times 10^{-8}$) risk locus from the meta-639 640 analysis by using the UKB LD. Iteratively, we chose the variant with the smallest Pvalue as the index variant and excluded all variants that had $r^2 \ge 0.1$ with the index 641 variant, until no variant had $P < 5 \times 10^{-8}$. Next, we formed high LD regions around 642 each index variant based on the combined UKB-FG LD and r² threshold of 0.6. The 643 644 start of the high LD region was the smallest position, and the end of the region was 645 the largest position where any variant had r²>0.6 with the index variant. Next, we 646 formed the loci by adding \pm 250 kb around the high LD region and merged the 647 overlapping regions. Further, we iteratively added all other GWS variants to their 648 closest loci, and updated the loci boundaries if any of the variants added were 649 outside the existing locus boundaries. Again, the overlapping loci were merged. We named each locus by the lead variant, i.e., the variant with the smallest P-value of 650 651 the locus.

652

653 Replication in HUNT All-in Headache and IHGC16

654

To replicate our new loci, we used two independent data sets with no overlaps with our GWAS data: HUNT All-in Headache²⁸ (N=40,224, 7,801 cases, 32,423 controls) and IHGC16 migraine meta-analysis⁹ excluding 23andMe and the Finnish cohorts (N = 189,000, 27,006 migraine cases and 161,994 controls). The meta-analysis of the replication data thus contained N=229,224 samples (34,807 cases and 194,417

controls). We used a one-sided P-value threshold of 0.05 to denote a replication and 660 661 assessed consistency of the effect directions by a sign test. We also reported the two-sided P-value of a combined analysis of our discovery and replication results to 662 663 determine which of the new loci remained GWS after observing the replication data. 664 Fine-mapping 665 666 For fine-mapping, we first merged loci that were closer than 1.5 Mb leading to 102 667 668 fine-map regions. We performed fine-mapping for each fine-map region with FINEMAP v1.4^{19,22}. FINEMAP is a Bayesian method that uses summary statistics 669 670 from a GWAS together with LD information to infer which variants are most likely 671 causal within the genomic region. We used the default prior parameters and set the 672 maximum number of causal variants to 10. 673 674 We estimated the in-sample LD correlations for the individual GWAS cohorts by using LDStore²². We combined the in-sample LD correlations for the meta-analysis 675 676 data set by combining the study-specific LD matrices by weighting each matrix in proportion to its effective sample size as follows: 677 678 $\mathbf{R} = (\mathbf{M}_1 \, \mathbf{R}_1 + \ldots + \mathbf{M}_C \, \mathbf{R}_C) \, / \, \mathbf{M},$ (F1) 679 680 where \mathbf{R}_i is the LD correlation matrix of study i, $M_i = 4N_i p_i (1-p_i)$ is the effective 681 sample size of study i, with N_i being the total sample size (i.e., the sum of cases and 682 controls) and p_i being the proportion of cases in study i, and M = M₁ + ... + M_C is the 683 sum of the effective sample sizes.

For the UK Biobank reference LD (UKB-LD), we used the in-sample LD estimatedfrom the individuals included in the UKB GWAS.

For the combined UKB-FG LD reference panel, we combined the UKB and FG insample LD matrices by weighting FG in proportion to its effective sample size, and
UKB in proportion to the combined UKB+23andMe effective sample size using the
above formula (F1).

691

692 LD reference panel sensitivity analyses

693

694 We compared the performance of different LD refence panels (UKB LD, UKB-FG LD

and in-sample LD) on the FINEMAP results for the 26 fine-map regions for which the

696 in-sample LD was available. We used the maximum difference between the posterior

inclusion probabilities (PIPs) from different panels (max Δ) to compare the

698 performance of the three LD panels.

699 In addition, we examined the following candidate statistics which could be used for

separating the fine-map regions for which the fine-mapping with the reference LD

performs poorly when compared to the use of the in-sample LD: 1) the posterior

roce expectation of the number of causal variants (PENC), and, from the top variant(s) of

the credible set(s) determined by FINEMAP, 2) the maximum pairwise r^2 , 3) the

maximum marginal *P*-value from the meta-analysis, or 4) the minimum INFO value.

705

706 Variant annotation by VEP and eQTL mapping

707

708 FINEMAP reports 95%-credible sets (CS). We searched for coding variants among

709 the CS from the Ensembl VEP

- 710 (http://grch37.ensembl.org/Homo sapiens/Tools/VEP) database by using a default of
- 5 kb window around the index variant.
- 712
- For the follow-up analyses, we formed a functional variant group among the CS
- variants by including the variants that were predicted by VEP to have a moderate or
- 715 high impact on the transcript
- 716 (https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html). This
- 717 includes transcript ablation, splice acceptor or donor variants, stop gained, frameshift
- variant, stop lost, start lost, transcript amplification, inframe insertion or deletion, and
- 719 missense variant.
- 720 We mapped the functional variant set, and also another set including all variants with
- PIP > 0.1 (highPIP), to significant eQTLs of the 49 tissues from GTEx v.8
- 722 (https://gtexportal.org/home/).
- 723
- 724 Phenome-wide association scans
- 725

726 We performed three phenome-wide association scans (PheWAS). First, we scanned all 181 candidate variants of the risk loci (top variants of the credible sets) among the 727 728 2,399 FinnGen Data Freeze 10 (R10) GWAS endpoints (excluding 9 migraine endpoints) at significance level 1×10^{-5} . Second, we scanned all variants annotated 729 as functional variants with a moderate to high impact on protein function by VEP 730 731 among neurological and cardiovascular endpoints from FinnGen R10, including the 732 FinnGen endpoint categories Neurological endpoints, VI Diseases of the nervous 733 system (G6), and IX Diseases of the circulatory system (I9) with at significance level 1×10^{-4} . 734

- Third, we scanned all variants with PIP > 0.1 among the same FinnGen neurological
- and cardiovascular endpoints at significance level 1×10^{-4} .
- 737 Results can be browsed from PheWAS app
- 738 https://hhautakangas.github.io/phewas_migraine_tables.html.
- 739

740 Data availability

- The access to the UK biobank data can be applied through
- 742 https://www.ukbiobank.ac.uk/
- The GWAS summary statistics for FinnGen R8 are publicly available through
- 744 https://www.finngen.fi/en/access_results. The Finnish biobank data can be accessed
- through the Fingenious® services (<u>https://site.fingenious.fi/en/</u>) managed by FINBB.
- Finnish Health register data can be applied from Findata (<u>https://findata.fi/en/data/</u>).
- 747 The GWAS summary statistics for the 23andMe data set will be made available
- through 23andMe to qualified researchers under an agreement with 23andMe that
- 749 protects the privacy of the 23andMe participants. Please visit
- 750 <u>https://research.23andme.com/collaborate/#publication</u> for more information and to
- apply to access the data.
- 752
- 753 Acknowledgements
- 754
- 755 We would like to thank the research participants and employees of 23andMe, Inc. for
- making this work possible. We thank all the study participants, employees, and
- investigators of FinnGen and the UK Biobank for their contribution to this research.
- This research has been conducted using the UK Biobank Resource under
- Application Number 22627. This work was supported by grants no. 336825, 338507,

352795 from the Research Council of Finland to M.P., by Sigrid Jusélius foundation 760 761 (M.P. and A.P.) and by the Doctoral School of University of Helsinki (H.H.). The FinnGen project is funded by two grants from Business Finland (HUS 762 763 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie 764 Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene 765 Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme 766 LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US 767 Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and 768 Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for 769 delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL 770 Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank 771 Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-772 opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical 773 Biobank Tampere (www.tays.fi/en-774 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of 775 Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank 776 (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank 777 778 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic 779 Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-780 medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are 781 members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -782 FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The 783 Finnish biobank data can be accessed through the Fingenious® services 784 (https://site.fingenious.fi/en/) managed by FINBB.

785	The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research
786	Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science
787	and Technology NTNU), Trøndelag County Council, Central Norway Regional Health
788	Authority, and the Norwegian Institute of Public Health. The genotyping was financed
789	by the National Institute of health (NIH), University of Michigan, The Norwegian
790	Research council, and Central Norway Regional Health Authority and the Faculty of
791	Medicine and Health Sciences, Norwegian University of Science and Technology
792	(NTNU). The genotype quality control and imputation has been conducted by the
793	K.G. Jebsen center for genetic epidemiology, Department of public health and
794	nursing, Faculty of medicine and health sciences, Norwegian University of Science
795	and Technology (NTNU).
796	
797	Consortia
798	A full list of FinnGen members and their affiliations appears in the Supplementary
799	Data 1.
800	
801	International Headache Genetics Consortium
802	Verneri Anttila ^{1,2,3} , Ville Artto ⁴ , Andrea C Belin ⁵ , Anna Bjornsdottir ⁶ , Gyda
803	Bjornsdottir ⁷ , Dorret I Boomsma ⁸ , Sigrid Børte ^{9,10,11} , Mona A Chalmer ¹² , Daniel I
804	Chasman ^{13,14} , Bru Cormand ¹⁵ , Ester Cuenca-Leon ¹⁶ , George Davey-Smith ¹⁷ , Irene
805	de Boer ¹⁸ , Martin Dichgans ^{19,20} , Tonu Esko ²¹ , Tobias Freilinger ^{22,23} , Padhraig
806	Gormley ²⁴ , Lyn R Griffiths ²⁵ , Eija Hämäläinen ²⁶ , Thomas F Hansen ^{12,27} , Aster VE
807	Harder ^{18,28} , Heidi Hautakangas ²⁶ , Marjo Hiekkala ²⁹ , Maria G Hrafnsdottir ³⁰ , M. Arfan
808	Ikram ³¹ , Marjo-Riitta Järvelin ^{32,33,34,35} , Risto Kajanne ²⁶ , Mikko Kallela ⁴ , Jaakko
809	Kaprio ²⁶ , Mari Kaunisto ²⁹ , Lisette JA Kogelman ¹² , Espen S Kristoffersen ^{36,37,38} ,

810	Christian Kubisch ³⁹ , Mitja Kurki ⁴⁰ , Tobias Kurth ⁴¹ , Lenore Launer ⁴² , Terho
811	Lehtimäki ⁴³ , Davor Lessel ³⁹ , Lannie Ligthart ⁸ , Sigurdur H Magnusson ⁷ , Rainer

- 812 Malik¹⁹, Bertram Müller-Myhsok⁴⁴, Carrie Northover⁴⁵, Dale R Nyholt⁴⁶, Jes Olesen¹²,
- 813 Aarno Palotie^{26,47}, Priit Palta²⁶, Linda M Pedersen⁴⁸, Nancy Pedersen⁴⁹, Matti
- ⁸¹⁴ Pirinen^{26,50,51}, Danielle Posthuma⁵², Patricia Pozo-Rosich⁵³, Alice Pressman⁵⁴, Olli
- 815 Raitakari^{55,56,57}, Caroline Ran⁵, Gudrun R Sigurdardottir⁶, Hreinn Stefansson⁷, Kari
- 816 Stefansson⁷, Olafur A Sveinsson³⁰, Gisela M Terwindt¹⁸, Thorgeir E Thorgeirsson⁷,
- 817 Arn MJM van den Maagdenberg^{18,28}, Cornelia van Duijn⁵⁸, Maija Wessman^{26,29},
- 818 Bendik S Winsvold^{9,48,59}, John-Anker Zwart^{9,10,48}
- 819

820 ¹Analytical and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital 821 and Harvard Medical School, Boston, Massachusetts, USA; ²Program in Medical and Population 822 Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; ³Stanley Center for 823 Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; 824 ⁴Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; ⁵Department of 825 Neuroscience, Karolinska Institutet, Stockholm, Sweden; ⁶Neurology private practice, Laeknasetrid, 826 Reykjavik, Iceland; ⁷deCODE genetics/Amgen Inc., Reykjavik, Iceland; ⁸Netherlands Twin Register, 827 Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands; ⁹K.G. Jebsen 828 Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and 829 Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; ¹⁰Institute of 830 Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ¹¹Research and 831 Communication Unit for Musculoskeletal Health, Department of Research, Innovation and Education, 832 Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway; ¹²Danish Headache Center, 833 Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark; ¹³Department of 834 Medicine, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, 835 USA; ¹⁴Harvard Medical School, Boston, Massachusetts, USA; ¹⁵Department of Genetics, Spain 836 Centre for Biomedical Network Research on Rare Diseases, University of Barcelona, Barcelona, 837 Spain; ¹⁶Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain; 838 ¹⁷University of Bristol/Medical Research Council Integrative Epidemiology Unit, University of Bristol, 839 Bristol, UK; ¹⁸Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands; 840 ¹⁹Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany; 841 ²⁰Munich Cluster for Systems Neurology, Munich, Germany; ²¹Estonian Biobank Registry, the 842 Estonian Genome Center, University of Tartu, Tartu, Estonia; ²²Department of Neurology, Klinikum 843 Passau, Passau, Germany; ²³Department of Neurology and Epileptology, Hertie Institute for Clinical

844 Brain Research, University of Tuebingen, Tuebingen, Germany; ²⁴GSK Inc., Cambridge, 845 Massachusetts, USA; ²⁵Centre for Genomics and Personalised Health, Queensland University of 846 Technology, Brisbane, Queensland, Australia; ²⁶Institute for Molecular Medicine Finland, Helsinki 847 Institute of Life Science, University of Helsinki, Helsinki, Finland; ²⁷Novo Nordic Foundation Center for 848 Protein Research, Copenhagen University, Copenhagen, Denmark; ²⁸Department of Human 849 Genetics, Leiden University Medical Centre, Leiden, the Netherlands; ²⁹Folkhälsan Research Center, 850 Helsinki, Finland; ³⁰Landspitali University Hospital, Revkjavik, Iceland; ³¹Department of Epidemiology, 851 Erasmus University Medical Center, Rotterdam, the Netherlands; ³²Department of Epidemiology and 852 Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College 853 London, London, UK; ³³Center for Life Course Health Research, Faculty of Medicine, University of 854 Oulu, Oulu, Finland; ³⁴Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland; 855 ³⁵Department of Life Sciences, College of Health and Life Sciences, Brunel University London, 856 London, UK; ³⁶Research and Communication Unit for Musculoskeletal Health, Department of 857 Research, Innovation and Education, Division of Clinical Neuroscience, Akershus University Hospital 858 and University of Oslo, Oslo, Norway; ³⁷Department of General Practice, Institute of Health and 859 Society, University of Oslo, Oslo, Norway; ³⁸Department of Neurology, Akershus University Hospital, 860 Lørenskog, Norway; ³⁹Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 861 Hamburg, Germany; ⁴⁰Psychiatric and Neurodevelopmental Genetics Unit, Department of Medicine, 862 Massachusetts General Hospital, Boston, Massachusetts, USA; ⁴¹Institute of Public Health, Charité – 863 Universitätsmedizin, Berlin; ⁴²Laboratory of Epidemiology and Population Sciences, Intramural 864 Research Program, National Institute on Aging, Bethesda, Maryland, USA; ⁴³Department of Clinical 865 Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of 866 Medicine and Health Technology, Tampere University, Tampere, Finland; ⁴⁴Max Planck Institute of 867 Psychiatry, Munich, Germany; ⁴⁵23&Me Inc., Mountain View, California, USA; ⁴⁶School of Biomedical 868 Sciences, Faculty of Health, Centre for Genomics and Personalised Health, Centre for Data Science, 869 Queensland University of Technology, Brisbane, Queensland, Australia; ⁴⁷University of Helsinki, 870 Helsinki, Finland; ⁴⁸Department of Research, Innovation and Education, Division of Clinical 871 Neuroscience, Oslo University Hospital, Oslo, Norway; 49Department of Medical Epidemiology and 872 Biostatistics, Karolinska Institutet, Stockholm, Sweden; ⁵⁰Department of Mathematics and Statistics, 873 University of Helsinki, Helsinki, Finland; ⁵¹Department of Public Health, University of Helsinki, Helsinki, 874 Finland; ⁵²Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive 875 Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands; 876 ⁵³Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; 877 ⁵⁴Sutter Health, Sacramento, California, USA; ⁵⁵Centre for Population Health Research, University of 878 Turku, Turku University Hospital, Turku, Finland; ⁵⁶Research Centre of Applied and Preventive 879 Cardiovascular Medicine, University of Turku, Turku, Finland; ⁵⁷Department of Clinical Physiology and 880 Nuclear Medicine, Turku University Hospital, Turku, Finland; ⁵⁸Department of Epidemiology, Erasmus 881 University Medical Centre, Rotterdam, the Netherlands; ⁵⁹Department of Neurology, Oslo University 882 Hospital, Oslo, Norway

885 HUNT All-in Headache

886	Amy E Martinsen ^{1,2,3} , Anne Heidi Skogholt ³ , Ben M Brumpton ³ , Bendik S
887	Winsvold ^{4,5,6} , Cristen J Willer ⁷ , Erling Tronvik ^{8,9} , Espen Saxhaug Kristoffersen ^{1,10,11} ,
888	John-Anker Zwart ^{1,2,3} , Jonas B Nielsen ^{3,7,12} , Knut Hagen ⁸ , Kristian Hveem ^{3,13,14} ,
889	Kristian Bernhard Nilsen ^{8,15} , Lars G Fritsche ¹⁶ , Lars Jacob Stovner ^{8,17} , Laurent F
890	Thomas ^{3,18,19,20} , Linda M Pedersen ¹ , Maiken E Gabrielsen ³ , Marianne B Johnsen ^{3,21} ,
891	Marie U Lie ^{2,21} , Oddgeir L Holmen ¹³ , Sigrid Børte ^{2,3,21} , Wei Zhou ^{22,23}

892

893 ¹Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, 894 Oslo, Norway, ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, 895 ³K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of 896 Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 897 Trondheim, Norway, ⁴Department of Research and Innovation, Division of Clinical Neuroscience, Oslo 898 University Hospital, Oslo, Norway, ⁵K. G. Jebsen Center for Genetic Epidemiology, Department of 899 Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of 900 Science and Technology (NTNU), Trondheim, Norway, ⁶Department of Neurology, Oslo University 901 Hospital, Oslo, Norway, ⁷Department of Internal Medicine, Division of Cardiovascular Medicine, 902 University of Michigan, Ann Arbor, MI, 48109, USA, 8Department of Neuromedicine and Movement 903 Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology 904 (NTNU), Trondheim, Norway, ⁹Department of Neurology and Clinical Neurophysiology, St. Olays 905 Hospital, Trondheim University Hospital, Trondheim, Norway, ¹⁰Department of General Practice, 906 University of Oslo, Oslo, Norway, ¹¹Department of Neurology, Akershus University Hospital, 907 Lørenskog, Norway, ¹²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 908 Denmark, ¹³HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine 909 and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 910 ¹⁴Department of Research, Innovation and Education, St. Olavs Hospital, Trondheim University 911 Hospital, Trondheim, Norway, ¹⁵Department of Neurology, Oslo University Hospital, Oslo, Norway, 912 ¹⁶Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, 913 48109, USA, ¹⁷Norwegian Advisory Unit on Headaches, St. Olavs Hospital, Trondheim University 914 Hospital, Trondheim, Norway, ¹⁸Department of Clinical and Molecular Medicine, Norwegian University 915 of Science and Technology (NTNU), Trondheim, Norway, ¹⁹BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ²⁰Clinic of Laboratory 916 917 Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ²¹Research and 918 Communication Unit for Musculoskeletal Health (FORMI), Department of Research and Innovation, 919 Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway, ²²Department of

- 920 Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA,
- 921 ²³Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 922
- 923 Competing interests
- 924
- 925 A.P. is the Scientific Director of the public-private partnership project FinnGen that
- has 12 industry partners that provide funding for the FinnGen project.
- 927 Other authors report no conflicts of interests.
- 928

930 References:

931

932 1. (IHS), H.C.C.o.t.I.H.S. Headache Classification Committee of the International 933 Headache Society (IHS) The International Classification of Headache Disorders, 3rd 934 edition. Cephalalgia 38, 1-211 (2018). 935 2. Vos, T. et al. Global burden of 369 diseases and injuries in 204 countries and 936 territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 937 2019. The Lancet 396, 1204-1222 (2020). 938 3. Gervil, M., Ulrich, V., Kaprio, J., Olesen, J. & Russell, M.B. The relative role of genetic 939 and environmental factors in migraine without aura. Neurology 53, 995-999 (1999). 940 Anttila, V. et al. Genome-wide association study of migraine implicates a common 4. 941 susceptibility variant on 8q22.1. Nature Genetics 42, 869-873 (2010). 942 5. Chasman, D.I. et al. Genome-wide association study reveals three susceptibility loci 943 for common migraine in the general population. Nature Genetics 43, 695-U116 944 (2011). 945 6. Freilinger, T. et al. Genome-wide association analysis identifies susceptibility loci for 946 migraine without aura. Nature Genetics 44, 777-782 (2012). 947 Anttila, V. et al. Genome-wide meta-analysis identifies new susceptibility loci for 7. 948 migraine. Nature Genetics 45, 912-U255 (2013). 949 Pickrell, J.K. et al. Detection and interpretation of shared genetic influences on 42 8. 950 human traits. Nature Genetics 48, 709-717 (2016). 951 Gormley, P. et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci 9. 952 for migraine. Nature Genetics 48, 856-866 (2016). 953 10. Chen, S.-P. et al. Genome-wide association study identifies novel susceptibility loci 954 for migraine in Han Chinese resided in Taiwan. Cephalalgia 38, 466-475 (2018). 955 11. Chang, X. et al. Common variants at 5q33.1 predispose to migraine in African-956 American children. Journal of Medical Genetics 55, 831 (2018). 957 Choquet, H. et al. New and sex-specific migraine susceptibility loci identified from a 12. 958 multiethnic genome-wide meta-analysis. Communications Biology 4, 864 (2021). 959 13. Hautakangas, H. et al. Genome-wide analysis of 102,084 migraine cases identifies 960 123 risk loci and subtype-specific risk alleles. Nature Genetics 54, 152-160 (2022). 961 Bjornsdottir, G. et al. Rare variants with large effects provide functional insights into 14. 962 the pathology of migraine subtypes, with and without aura. *Nature Genetics* 55, 963 1843-1853 (2023). 964 15. Finucane, H.K. et al. Heritability enrichment of specifically expressed genes identifies 965 disease-relevant tissues and cell types. Nature Genetics 50, 621-629 (2018). 966 16. Schaid, D.J., Chen, W. & Larson, N.B. From genome-wide associations to candidate 967 causal variants by statistical fine-mapping. Nature Reviews Genetics 19, 491-504 968 (2018). 969 Kichaev, G. et al. Integrating functional data to prioritize causal variants in statistical 17. 970 fine-mapping studies. PLoS Genet 10, e1004722 (2014). 971 Hormozdiari, F., Kostem, E., Kang, E.Y., Pasaniuc, B. & Eskin, E. Identifying causal 18. 972 variants at loci with multiple signals of association. Genetics 198, 497-508 (2014). 973 19. Benner, C. et al. FINEMAP: efficient variable selection using summary data from 974 genome-wide association studies. Bioinformatics 32, 1493-1501 (2016).

975	20.	Newcombe, P.J., Conti, D.V. & Richardson, S. JAM: A Scalable Bayesian Framework
976		for Joint Analysis of Marginal SNP Effects. <i>Genetic Epidemiology</i> 40 , 188-201 (2016).
977	21.	Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to
978		Variable Selection in Regression, with Application to Genetic Fine Mapping. Journal
979		of the Royal Statistical Society Series B: Statistical Methodology 82 , 1273-1300
980		(2020).
981	22.	Benner, C. et al. Prospects of Fine-Mapping Trait-Associated Genomic Regions by
982		Using Summary Statistics from Genome-wide Association Studies. American Journal
983		of Human Genetics 101 , 539-551 (2017).
984	23.	Kanal, M. et al. Meta-analysis fine-mapping is often miscalibrated at single-variant
985	~ .	resolution. <i>Cell Genomics</i> 2(2022).
986	24.	Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in
98/	25	schizophrenia. <i>Nature</i> 604 , 502-508 (2022).
988	25.	Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and
989	26	traits. Nature Genetics 47, 1236-1241 (2015).
990 001	26.	Isgut, IVI., Song, K., Enm, IVI.G., Wang, IVI.D. & Davitte, J. Effect of case and control
991		Children de Contraction Study (GWAS) Indings. Genetic
992	27	Epidemiology 47, 594-400 (2025). Mostchou L at al. Computationally officient whole geneme regression for
995 00/	27.	quantitative and binary traits. <i>Nature Genetics</i> 52, 1097-1103 (2021)
005	28	Krokstad S et al Cobort Profile: The HINT Study Norway International Journal of
996	20.	Enidemiology 42 , 968-977 (2012)
997	29	Yang A.W. Sachs A.L.& Nystuen A.M. Deletion of Inpn5a causes ataxia and
998	201	cerebellar degeneration in mice. <i>neurogenetics</i> 16 , 277-285 (2015).
999	30.	Liu. Q. <i>et al.</i> Cerebellum-enriched protein INPP5A contributes to selective
1000		neuropathology in mouse model of spinocerebellar ataxias type 17. Nature
1001		<i>Communications</i> 11 , 1101 (2020).
1002	31.	Zorzetto, M. et al. SERPINA1 Gene Variants in Individuals from the General
1003		Population with Reduced α 1-Antitrypsin Concentrations. Clinical Chemistry 54, 1331-
1004		1338 (2008).
1005	32.	Gupta, R.M. et al. A Genetic Variant Associated with Five Vascular Diseases Is a Distal
1006		Regulator of Endothelin-1 Gene Expression. Cell 170 , 522-533.e15 (2017).
1007	33.	Wang, X. & Musunuru, K. Confirmation of Causal rs9349379- <i>PHACTR1</i>
1008		Expression Quantitative Trait Locus in Human-Induced Pluripotent Stem Cell
1009		Endothelial Cells. Circulation: Genomic and Precision Medicine 11, e002327 (2018).
1010	34.	Guo, Dc. <i>et al.</i> Genetic Variants in LRP1 and ULK4 Are
1011		Associated with Acute Aortic Dissections. The American Journal of Human Genetics
1012		99 , 762-769 (2016).
1013	35.	Georges, A. et al. Genetic investigation of fibromuscular dysplasia identifies risk loci
1014		and shared genetics with common cardiovascular diseases. <i>Nature Communications</i>
1015		12 , 6031 (2021).
1016	36.	Turley, T.N. <i>et al.</i> Identification of Susceptibility Loci for Spontaneous Coronary
1017	27	Artery Dissection. JAMA Cardiology 5, 929-938 (2020).
1018	37.	Storck, S.E., Kurtyka, IVI. & Pietrzik, C.U. Brain endothelial LRP1 maintains blood-
1019	20	brain barrier integrity. <i>Fluids and Barriers of the CNS</i> 18 , 27 (2021).
1020	38.	LIU, Z., ANDRASKA, E., AKINDODE, D., Mars, W. & Alvidrez, K.I.M. LKP1 in the Vascular
1021		vvan. current Pathobiology Reports 10, 23-34 (2022).

1022 1023	39.	Lee, J. <i>et al.</i> ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells. <i>Nature Communications</i> 14 ,
1024		8463 (2023).
1025	40.	Liu, L. <i>et al.</i> Regulatory mechanisms in multiple vascular diseases locus
1026		LRP1 involve repression by SNAIL and extracellular matrix remodeling.
1027	11	DIORXIV, 2023.05.09.539992 (2023).
1028	41.	consciling, S., Auburger, G., Heumann, K., Scott, J. & Moenen, H. Levels of herve
1029		choliporgic inportation. The EMBO Journal 4, 1280-1202 (1985)
1030	12	Coppor B & Dragunow M The role of neuronal growth factors in
1031	42.	neurodegenerative disorders of the human brain <i>Brain Research Reviews</i> 27 1-39
1032		(1998)
1034	43.	van Dongen, R.M. <i>et al.</i> Migraine biomarkers in cerebrospinal fluid: A systematic
1035		review and meta-analysis. <i>Cenhalalaia</i> 37 , 49-63 (2017).
1036	44.	Mozafarihashiin, M. <i>et al.</i> Assessment of peripheral biomarkers potentially involved
1037		in episodic and chronic migraine: a case-control study with a focus on NGF. BDNF.
1038		VEGF, and PGE2. The Journal of Headache and Pain 23 , 3 (2022).
1039	45.	Aloe, L., Tuveri, M.A., Carcassi, U. & Levi-Montalcini, R. Nerve growth factor in the
1040		synovial fluid of patients with chronic arthritis. Arthritis & Rheumatism 35 , 351-355
1041		(1992).
1042	46.	Freemont, A.J. et al. Nerve growth factor expression and innervation of the painful
1043		intervertebral disc. The Journal of Pathology 197 , 286-292 (2002).
1044	47.	Walsh, D.A. et al. Angiogenesis and nerve growth factor at the osteochondral
1045		junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 49, 1852-
1046		61 (2010).
1047	48.	Sanga, P. et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth
1048		factor antibody, in the treatment of patients with moderate to severe osteoarthritis
1049		pain. <i>Pain</i> 154 , 1910-1919 (2013).
1050	49.	Tiseo, P.J., Ren, H. & Mellis, S. Fasinumab (REGN475), an antinerve growth factor
1051		monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-
1052		concept study. Journal of Pain Research 7, 523-30 (2014).
1053	50.	Watt, F.E. <i>et al.</i> Iropomyosin-related kinase A (IrkA) inhibition for the treatment of
1054		paintui knee osteoarthritis: results from a randomized controlled phase 2a trial.
1055	F 1	Osteodrinniis Carliage 27 , 1590-1598 (2019).
1050	51.	officacy and safety results from a 24 week randomised phase III study with a 24-
1057		week follow-up period App Rheum Dis 79 , 800-810 (2020)
1058	52	Wise BI Seidel ME & Lane NE The evolution of nerve growth factor inhibition
1060	52.	in clinical medicine Nature Reviews Rheumatology 17 34-46 (2021)
1061	53	Kova Y et al. A novel anti-NGE PEGylated Eab' provides analgesia with lower risk of
1062	55.	adverse effects. <i>mAbs</i> 15 , 2149055 (2023).
1063	54.	Detke, H.C. <i>et al.</i> Galcanezumab in chronic migraine: The randomized, double-blind,
1064		placebo-controlled REGAIN study. <i>Neurology</i> 91 , e2211-e2221 (2018).
1065	55.	Dodick, D.W. <i>et al.</i> ARISE: A Phase 3 randomized trial of erenumab for episodic
1066		migraine. <i>Cephalalgia</i> 38 , 1026-1037 (2018).
1067	56.	Ferrari, M.D. et al. Fremanezumab versus placebo for migraine prevention in
1068		patients with documented failure to up to four migraine preventive medication

1069		classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The
1070		Lancet 394 , 1030-1040 (2019).
1071	57.	De Smedt, F., Verjans, B., Mailleux, P. & Erneux, C. Cloning and expression of human
1072		brain type I inositol 1,4,5-trisphosphate 5-phosphatase High levels of mRNA in
1073		cerebellar Purkinje cells. <i>FEBS Letters</i> 347 , 69-72 (1994).
1074	58.	Rubin, S. et al. PHACTR-1 (Phosphatase and Actin Regulator 1) Deficiency in Either
1075		Endothelial or Smooth Muscle Cells Does Not Predispose Mice to Nonatherosclerotic
1076		Arteriopathies in 3 Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular
1077		Biology 42 , 597-609 (2022).
1078	59.	Kurth, T. et al. Migraine and risk of cardiovascular disease in women: prospective
1079		cohort study. <i>BMJ</i> 353 , i2610 (2016).
1080	60.	Bycroft, C. <i>et al.</i> The UK Biobank resource with deep phenotyping and genomic data.
1081		Nature 562 , 203-209 (2018).
1082	61.	Kurki, M.I. et al. FinnGen provides genetic insights from a well-phenotyped isolated
1083		population. <i>Nature</i> 613 , 508-518 (2023).
1084	62.	Chang, C.C. et al. Second-generation PLINK: rising to the challenge of larger and
1085		richer datasets. <i>GigaScience</i> 4 , s13742-8 (2015).
1086	63.	Manichaikul, A. et al. Robust relationship inference in genome-wide association
1087		studies. <i>Bioinformatics</i> 26 , 2867-2873 (2010).
1088	64.	Hinrichs, A.S. et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids
1089		Research 34 , D590-8 (2006).
1090	65.	Mägi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-
1091		analysis. BMC bioinformatics 11, 288 (2010).
1092	66.	Bulik-Sullivan, B. et al. LD Score regression distinguishes confounding from
1093		polygenicity in genome-wide association studies. Nature genetics 47, 291-295
1094		(2015).
1095	67.	Lee, S.H., Wray, N.R., Goddard, M.E. & Visscher, P.M. Estimating missing heritability
1096		for disease from genome-wide association studies. American Journal of Human
1097		Genetics 88 , 294-305 (2011).
1098		